Roche’s sefaxersen significantly reduced proteinuria in a Phase 3 IgA nephropathy (IgAN) trial, but the Swiss pharma stopped ...

UK biotech Scarlet Therapeutics will lead a consortium developing red blood cells that can sense physiological changes and respond to them under a U.S. Defense Advanced Research Projects Agency (DARPA ...

London-based Big Picture Bio has launched with £2.2 million (€2.6 million) in funding to build an AI platform that designs drug combinations for cancer, starting largely with medicines that are ...

Boehringer Ingelheim has partnered with New York-based Envisagenics to hunt for new targets in hard-to-treat solid tumors, opening up more than $1 billion (€873 million) in potential payments.

It’s been nearly a decade since the first CAR-T cancer cell therapy was approved by the FDA, offering a powerful and durable­ ­therapy against tumours. But when it comes to fighting solid tumours, CAR ...

Belgian biotech Remynd has secured a €3.5 million investment from the Alzheimer’s Drug Discovery Foundation (ADDF) to move ...

Novartis has licensed an undisclosed preclinical radioligand therapy from China’s BoomRay Pharmaceuticals in a deal worth up to $900 million (€786 million), adding another asset to one of the pharma ...

New data from the World Conference on Lung Cancer in Seoul are giving BioNTech’s oncology strategy more substance beyond its ...

Australian radiopharma company Telix Pharmaceuticals has agreed to acquire Munich-based ITM Isotope Technologies for an ...

Beacon Therapeutics' gene therapy laru-zova met its U.S. pivotal endpoint in X-linked retinitis pigmentosa, while results on the trial's separately designated European primary efficacy measure were ...

Novartis has stopped developing its TREM2 antibody VHB937 (lifonebart) in amyotrophic lateral sclerosis (ALS) after the ...

The European Investment Bank (EIB) is providing German Ethris with €30 million to advance clinical development of its ...